How well Solidago virgaurea mother tincture works as an add on treatment in reducing the remaining urine in the bladder after urination in patients with urinary retention problems: An open study with randomly assigned groups.

EFFECTIVENESS OF SOLIDAGO VIRGAUREA Q AS AN ADD-ON THERAPY IN REDUCING POST-VOID RESIDUAL URINE IN PATIENTS WITH URINARY RETENTION DISORDERS: AN OPEN-LABEL RANDOMISED CONTROLLED TRIAL - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/09/094342

Enrollment

126

Registered

2025-09-08

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N33- Bladder disorders in diseases classified elsewhere

Interventions

Intervention1: INDIVIDUALIZED HOMOEOPATHIC MEDICINE PLUS SOLIDAGO VIRGAUREA MOTHER TINCTURE: The dose and repetition of medicines, including mother tinctures, may vary according to the susceptibility

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients giving consent. 2.Patients maintaining proper follow-up. 3.Diagnosed cases of elevated post-void residual urine (i.e,more than 10 percent of pre void urine) confirmed by ultrasound/bladder scan or catheterisation. 4.Patients willing to undergo individualized homoeopathic treatment and comply with the trial protocol. 5.Patients presenting with symptoms of urinary retention disorders such as incomplete voiding, frequent urging, burning micturition or sensation of fullness, urine incontinence etc. 6.Patients currently on alpha-blockers, anticholinergics, or other modern medications, phytotherapy or herbal urinary medication specifically targeting urinary retention disorders, still not getting relief.

Exclusion criteria

Exclusion criteria: 1.Patients who do not provide consent. 2.Patient fails to maintain proper follow-up. 3.Patients with complete retention of urine for more than 24 hours. 4.Patients are on dialysis. 5.Patient with vesicoureteral reflex. 6.Pregnant or lactating women. 7.Known hypersensitivity or intolerance to Solidago virgaurea or any other constituents of the preparation.

Design outcomes

Primary

Measure	Time frame
PARTICIPANTS RECEIVING SOLIDAGO VIRGAUREA MOTHER TINCTURE ALONG WITH INDIVIDUALIZED HOMOEOPATHIC MEDICINES ARE EXPECTED TO SHOW A GREATER REDUCTION IN THE POST VOID RESIDUAL URINE COMPARED TO THOSE RECEIVING INDIVIDUALIZED HOMOEOPATHIC TREATMENT ALONETimepoint: PRE AND POST VOID OF URINE WILL BE ASSESSED BASED ON ALTERATIONS IN ULTRASOUND BLADDER SCAN OR CATHETERISATION AT THE END OF 3 MONTHS	—

Secondary

Measure	Time frame
AT THE END OF THE STUDY WE EXPECT THAT SOLIDAGO VIRGAUREA MOTHER TINCTURE NOT ONLY MANAGED THE POST VOID RESIDUAL URINE BUT ALSO ITS COMORBIDITIES(USING DAILY BLADDER DIARY)Timepoint: 12 MONTHS;MOTHER TINCTURE DOSES ARE EMPIRICALLY DERIVED AND NOT YET RIGOROUSLY VALIDATED; THEREFORE, THIS STUDY WILL CONTRIBUTE TOWARD DOSE VALIDATION. THE TRIAL IS EXPECTED TO GENERATE DATA TO SUPPORT FUTURE DOSE?RESPONSE EVALUATIONS AND FACILITATE EVIDENCE-BASED REFINEMENT OF MOTHER TINCTURE USE IN HOMOEOPATHY AS AN ADD-ON THERAPY.Timepoint: 12 MONTHS	—

Measure

Time frame

AT THE END OF THE STUDY WE EXPECT THAT SOLIDAGO VIRGAUREA MOTHER TINCTURE NOT ONLY MANAGED THE POST VOID RESIDUAL URINE BUT ALSO ITS COMORBIDITIES(USING DAILY BLADDER DIARY)Timepoint: 12 MONTHS;MOTHER TINCTURE DOSES ARE EMPIRICALLY DERIVED AND NOT YET RIGOROUSLY VALIDATED; THEREFORE, THIS STUDY WILL CONTRIBUTE TOWARD DOSE VALIDATION. THE TRIAL IS EXPECTED TO GENERATE DATA TO SUPPORT FUTURE DOSE?RESPONSE EVALUATIONS AND FACILITATE EVIDENCE-BASED REFINEMENT OF MOTHER TINCTURE USE IN HOMOEOPATHY AS AN ADD-ON THERAPY.Timepoint: 12 MONTHS

—

Countries

India

Contacts

Public ContactDr RAGHUKUL AMAR DUBEY

Dr MPK HOMOEOPATHIC MEDICAL COLLEGE, HOSPITAL AND RESEARCH CENTRE

drcssharma.jaipur@gmail.com9314539277

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026